Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Common Equity (2016 - 2025)

Aptevo Therapeutics' Common Equity history spans 11 years, with the latest figure at $17.4 million for Q3 2025.

  • For Q3 2025, Common Equity rose 293.48% year-over-year to $17.4 million; the TTM value through Sep 2025 reached $17.4 million, up 293.48%, while the annual FY2024 figure was $4.8 million, 61.09% down from the prior year.
  • Common Equity for Q3 2025 was $17.4 million at Aptevo Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $23.3 million in Q1 2023 and bottomed at -$5.9 million in Q1 2022.
  • The 5-year median for Common Equity is $10.5 million (2021), against an average of $10.1 million.
  • The largest YoY upside for Common Equity was 1378.12% in 2022 against a maximum downside of 156.02% in 2022.
  • A 5-year view of Common Equity shows it stood at $1.2 million in 2021, then skyrocketed by 1378.12% to $18.0 million in 2022, then tumbled by 32.01% to $12.2 million in 2023, then plummeted by 61.09% to $4.8 million in 2024, then skyrocketed by 265.76% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Common Equity are $17.4 million (Q3 2025), $6.5 million (Q2 2025), and -$1.5 million (Q1 2025).